ALVO: FDA Resubmissions And 2026 Biosimilar Launch Plan Will Drive Upside

Analysts have trimmed their average price target on Alvotech to about $13.83 from $14.00, linking the change to updated views on future P/E assumptions, as well as adjusted expectations for revenue growth and profit margins.

Analyst Commentary

Recent Street research on Alvotech points to a mixed but focused view on the stock, with several firms adjusting price targets and updating their assumptions around P/E, revenue growth, and margins.

Bullish Takeaways

Bullish analysts appear comfortable that current valuation assumptions still reflect Alvotech's business model, even after trimming price targets, which suggests they see support for the stock at revised levels.
Some commentary implies confidence that revenue growth expectations, while adjusted, remain intact enough to justify a premium to companies with less visible pipelines.
There is an indication that analysts who are constructive on the stock continue to factor in margin expansion potential over time, which helps underpin their longer term P/E frameworks.
Bullish analysts also seem to view recent target changes as a recalibration of models rather than a complete reset of the investment case, which can matter for investors focused on execution over multiple years.

Bearish Takeaways

Bearish analysts are using lower price targets to reflect more cautious views on how quickly Alvotech can translate its opportunities into revenue, which directly feeds into trimmed growth assumptions.
There is concern that profit margins could track below prior expectations, which would limit earnings power and may cap the P/E that investors are willing to pay.
Some research suggests that execution risk around key milestones is now being given more weight in models, leading to more conservative valuation inputs.
Bearish analysts also seem wary that if revenue and margin outcomes land closer to the lower end of their updated ranges, the stock could appear fully valued even at the reduced average target.

What’s in the News

Alvotech reported 2025 revenue growth of 21% and is targeting 2026 revenues between US$650 million and US$700 million, with contributions from both product and licensing revenues. Source: company news summary.
The company has resubmitted Biologics License Applications to the U.S. FDA for biosimilars AVT03, AVT05 and AVT06 after implementing more than 200 corrective and preventive actions at its Reykjavik manufacturing facility, and expects a six month review period. Source: company news summary.
Alvotech is planning for up to five biosimilars to be on the U.S. market by year end 2026 and continues to advance a pipeline of 30 biosimilars, supported by a commercialization partnership with Teva Pharmaceutical Industries. Source: company news summary.
To increase manufacturing capacity and supply resilience, Alvotech is expanding production through a partnership with Fujifilm for a second U.S. site, aimed at strengthening its commercial footprint. Source: company news summary.
Following an FDA inspection of the Reykjavik facility that resulted in a Form 483, Alvotech submitted responses and continued quality and manufacturing improvements, which supported the resubmission of AVT05 and AVT06 BLAs under the Teva partnership. Source: company key developments.

Valuation Changes

Fair Value: The average fair value estimate has edged down slightly from $14.00 to about $13.83 per share.
Discount Rate: The discount rate used in models has been reduced from 9.13% to about 8.73%, which reflects a lower required return in updated assumptions.
Revenue Growth: Forecast revenue growth assumptions have been raised from about 18.52% to roughly 22.63%.
Profit Margin: Expected profit margin has shifted higher from about 19.33% to roughly 21.55% in current models.
Future P/E: The future P/E multiple applied has decreased from about 36.7x to roughly 24.9x.

8 views

Key Takeaways

Accelerating global biosimilar adoption and strategic partnerships expand Alvotech's market reach, boosting future revenue stability and margin potential.
Vertical integration and acquisitions improve operational efficiency and resilience, supporting sustainable earnings growth amid industry-wide cost pressures.
Reliance on unpredictable milestone payments, intense price competition, high fixed costs, heavy partner concentration, and regulatory risks threaten revenue stability, margin health, and long-term profitability.

Catalysts

About Alvotech

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.What are the underlying business or industry changes driving this perspective?

Alvotech's expanding global rollout and market share gains for its leading biosimilars, especially Humira and STELARA, signal continued growth as payers worldwide accelerate the shift to biosimilars-directly supporting future revenue and cash flow growth.
Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.
Strengthened strategic partnerships (e.g., Advanz Pharma, Teva, Dr. Reddy's) and expanding distribution footprint enable Alvotech to rapidly access new regions and patient pools as governments seek more cost-effective treatment options, likely enhancing future revenue predictability and operating margins.
Investments in vertical integration and acquisitions (Xbrane R&D, Ivers-Lee) improve operational control and cost efficiencies, expected to enhance gross margin resilience and support sustainable earnings growth amid industry-wide margin pressures.
Sustained global trends of aging populations and rising chronic diseases are structurally increasing demand for biologic therapies, expanding the biosimilar addressable market and underpinning long-term revenue visibility and upside for Alvotech.

Alvotech Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Alvotech's revenue will grow by 22.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -14.4% today to 21.6% in 3 years time.
Analysts expect earnings to reach $223.4 million (and earnings per share of $0.86) by about June 2029, up from -$80.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $342.5 million in earnings, and the most bearish expecting $81.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.9x on those 2029 earnings, up from -13.7x today. This future PE is greater than the current PE for the US Biotechs industry at 16.6x.
Analysts expect the number of shares outstanding to grow by 0.13% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.73%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Alvotech's guidance and revenue recognition are highly dependent on milestone payments tied to regulatory approvals, which are described as "lumpy" and unpredictable-delays in product approvals or shifts in regulatory timelines (such as FDA inspections or BsUFA date movements) could cause significant shortfalls in revenue, impacting both top-line and earnings volatility in the long term.
The biosimilar industry, especially in products like Humira and STELARA, faces intensifying price competition, with management highlighting "very competitive" pricing and unsustainably low offers from rivals-this pressure could lead to deteriorating net margins and erode profitability over the long term, especially as payer cost-containment becomes more aggressive globally.
Heavily increased R&D investment and recent acquisitions (e.g., Xbrane R&D and Ivers-Lee) add to Alvotech's fixed cost base at a time when cash flow, while improved, is still overshadowed by a high debt load ($1,139 million in debt versus $151 million in cash); if future launches or approvals are delayed or underperform, this could threaten liquidity, force dilutive equity issuance, or increase leverage, directly impacting shareholder value.
Alvotech's dependency on a small number of commercialization partners like Teva, Quallent and STADA for market access in key geographies introduces concentration risk-any unfavorable renegotiation, contract termination, or underperformance by these partners could lead to sudden revenue and market share declines, increasing volatility and reducing earnings visibility.
Regulatory scrutiny-particularly increased FDA and global inspections, or shifting standards for biosimilar approvals-remains a material risk; even "ordinary course" delays or raised quality hurdles could slow time-to-market for pipeline assets, limiting revenue growth and risking further lumpiness or outright misses on financial targets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $13.83 for Alvotech based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $4.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.0 billion, earnings will come to $223.4 million, and it would be trading on a PE ratio of 24.9x, assuming you use a discount rate of 8.7%.
Given the current share price of $3.54, the analyst price target of $13.83 is 74.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Alvotech?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks